Loading
TG
Tonghua Golden-Horse Pharmaceutical Industry Co,Ltd Stock: price and insider trades · China
通化金马
No insider purchase over the last 90 days. The latest, by 张玉富, was filed 02 Jul 2026.
Tonghua Golden-Horse Pharmaceutical Industry Co,Ltd: what insiders have been doing
This page follows insider dealings at Tonghua Golden-Horse Pharmaceutical Industry Co,Ltd as filed with SSE / SZSE (CSRC), a company from the Health Care sector. In the past year (20 October 2025 to 20 October 2026), 2 filings came from 1 insider.
The flow runs one way only: 1 insider bought (2 purchases totalling €2.4M) and nobody sold on the market. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. At €1.3M, the purchase published on 23 March 2026 by 张玉富 is the largest of the period. The buyers include 1 board member.
The most recent open-market purchase was published on 2 July 2026, 110 days ago.
Compared with its exchange (533 companies, median 2 filings), a count of 2 filings is typical. The full history, which starts in 2026, counts 2 purchases against no sales.
Other companies in the same sector with recent insider buying flagged by our signals: MAIA Biotechnology, Inc. and Cooper Companies, Inc. Every figure here comes from the filings published by SSE / SZSE (CSRC) and describes the past, not future prices; it is not investment advice.
Insider Decl.
2
Thresholds
n/a
Buy Volume
€2M
2 ops. · all time
Sell Volume
n/a
n/a
Who traded when
BuySale张玉富2 buys
Since the insiders bought
- -18.0%Entry CN¥17.55 · Close 13 Oct 2026 CN¥14.39
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 18,091 of 26,407 companies
39.3
score / 100
Value37
Quality42
FCF yld0.3%
Earn yld0.2%
EV/EBITDA·
ROE1.1%
Gross mgn72%
Net mgn2.9%
Debt/EBITDA9.7x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
CN¥14.52
Analyst consensus
Income statement
RevenueCN¥1.2B
Gross profitCN¥843.9M72% margin
EBITDACN¥187M16% margin
Net incomeCN¥34.3M2.3% margin
Valuation
PER (trailing)484.0x
P/Book6.1x
Beta0.53
Balance sheet & cash
Market capCN¥14B
Total debtCN¥1.8B
Free Cash FlowCN¥41M
Debt / Equity87%
Profitability & ownership
ROE1.1%
ROA1.4%
% insiders36.8%
% institutions3.7%
Last declaration on 2 July 2026
About Tonghua Golden-Horse Pharmaceutical Industry Co,Ltd
Tonghua Golden Horse is a company operating in the healthcare and pharmaceutical sector, listed on the XSHE market. It focuses on the research, development, and production of pharmaceuticals.
